G6PD deficiency patterns along Lake Victoria sharpen the case for routine malaria pharmacogenetics
Among communities around Kenya’s Lake Victoria basin, glucose-6-phosphate dehydrogenase deficiency appears common enough to shape malaria treatment decisions, yet not common enough to be ignored as a niche genetic curiosity. In a cohort of 1,661 individuals from five communities in Homa Bay County, deficiency was identified in 6.8% overall, with a clear sex difference: 9.0% in males and 4.9% in females. The biology behind the finding is familiar to malaria clinicians, but the public health consequence is increasingly urgent. Primaquine remains central to clearing dormant Plasmodium vivax and P. ovale hypnozoites and reducing P. falciparum gametocytes, yet safety concerns in G6PD-deficient patients continue to constrain its uptake across sub-Saharan Africa.
The study places a hard genetic boundary around a problem that often gets discussed in general terms. Deficiency was primarily explained by the G202A variant, corresponding to G6PD A-/Asahi. Among 104 G6PD-deficient participants who underwent genotyping, 66 were hemizygous, 26 homozygous, and 7 heterozygous for G6PD A- or Asahi variants. Whole-gene sequencing added one more layer of complexity, revealing G6PD Sibari (A634G) in a deficient male. In practical terms, this is not a single-mutation population or a tidy binary between normal and abnormal enzyme activity. The local mutation mix matters because primaquine risk assessment depends on knowing whether deficiency is driven by the common A- background or by additional, less frequently detected variants.
The study also reaffirms why enzymatic testing cannot be treated as an academic exercise before antimalarial prescribing. G6PD is the rate-limiting enzyme in the pentose phosphate pathway, and its downstream production of NADPH protects red blood cells from oxidative injury. When that antioxidant defense is weakened, oxidant stress from 8-aminoquinoline therapy can precipitate haemolysis. The concern is not theoretical in a malaria-endemic setting where treatment decisions are made close to the bedside, often with limited lab support. A patient who appears eligible for radical cure may, in fact, be sitting on a level of enzyme vulnerability that turns a useful drug into a haemolytic trigger.
No detectable protective effect against Plasmodium infection
G6PD deficiency did not protect against Plasmodium infection in this cohort. That finding matters because the protective hypothesis has long circulated in malaria genetics, particularly in populations where deficiency remains common. Here, the relationship was not borne out. Instead, microscopic infection tracked with a different cluster of risk markers: living in communities with higher parasite prevalence, male sex, young age, severe anaemia, and bed net disuse. The signal is epidemiologically cleaner than the protection hypothesis and far more actionable at the population level.
One sentence captures the clinical asymmetry: G6PD deficiency was common, but it did not confer measurable protection against Plasmodium infection.
The association between microscopic infection and severe anaemia is especially important in this setting. Anaemia in malaria-endemic communities rarely has a single cause, and G6PD deficiency itself can amplify vulnerability to haemolysis under oxidative stress. Yet the present data do not support treating deficiency as a shield against infection. Instead, they point toward overlapping risks: parasitaemia, anaemia, and enzyme deficiency can coexist in the same individuals, complicating both prognosis and drug choice. Bed net disuse adds a behavioral dimension that is easy to miss when genetic discussions dominate the conversation, but it remains a direct lever for prevention.
Why the local variant mix matters for primaquine use
Primaquine’s value in malaria elimination is inseparable from the safety problem it creates in deficient patients. Its oxidant properties are exactly what make it effective against dormant liver stages and gametocytes, and exactly what make clinicians cautious when G6PD status is unknown. In this Kenyan cohort, the predominance of G202A-linked deficiency suggests that standard African variant patterns still dominate, but the detection of a whole-gene sequence variant in a deficient male is a reminder that targeted genotyping can miss biologic outliers. Enzyme testing and genotype testing answer related but not identical questions. One tells clinicians how the red cell is functioning now; the other identifies the inherited risk architecture that may explain that function.
The X-linked inheritance pattern also explains the sex split. Males, who carry a single X chromosome, are more likely to express deficiency when they inherit a pathogenic allele, while females can be mosaic for enzyme activity depending on heterozygosity and X-inactivation. The observed prevalence gap between males and females fits that biology without requiring any embellishment. In malaria-endemic areas, this has bedside relevance because a single test result can change whether primaquine is deferred, modified, or avoided altogether.
What the Lake Victoria data demand from malaria programs
The study’s most consequential message is not simply that G6PD deficiency exists in western Kenya. It is that deficiency is common enough to influence medication policy, and its local genetic basis is sufficiently specific to justify careful implementation of testing strategies. Primaquine scale-up cannot depend on assumptions drawn from broader regional averages alone. A field clinician deciding whether to prescribe an 8-aminoquinoline needs reliable information about enzyme activity, not just a map of malaria prevalence.
This becomes even more relevant as non-falciparum malaria and artemisinin-resistant P. falciparum remain concerns in sub-Saharan Africa. When radical cure and transmission interruption depend on a drug class with a known haemolytic liability, the threshold for better screening becomes lower, not higher. The logic is straightforward: if the treatment is effective but potentially dangerous in a definable subgroup, then the subgroup has to be identifiable before therapy starts.
One practical consequence follows immediately from the data: malaria control programs in these communities will need to balance expanded access to primaquine with the reality of G6PD deficiency screening gaps. The study does not resolve how best to deploy testing in low-resource settings, nor does it provide a full operational blueprint for routine rollout. It does show that the combination of frequent deficiency, predominant G202A-linked variants, and ongoing malaria transmission creates a setting where ignoring pharmacogenetics carries a foreseeable haemolysis risk.
The next clinical question is not whether G6PD matters in this region. It clearly does. The unresolved issue is how quickly malaria programs can integrate dependable testing into frontline care while preserving access to drugs that remain essential for elimination efforts.